Arcturus Therapeutics Holdings Inc. filed a Form 8-K on November 16, 2026, disclosing a $50.0 million stock sale to Meiji Seika Pharma Co., Ltd. and concurrent collaboration agreements, including a license and a non-binding memorandum of understanding.
Key Highlights
- Share sale: Arcturus sold 2,466,395 shares of common stock (par value $0.001 per share) to Meiji Seika Pharma Co., Ltd. for an aggregate purchase price of $50.0 million.
- Premium pricing: According to the filing, the purchase price represents a premium of 80% to the average closing price of the common stock over the 30 trading days through and including November 11, 2026.
- Potential refund obligation: If a definitive license agreement contemplated by the MOU is not entered into by May 31, 2027, the company is required to refund to Meiji 50% of the premium, or approximately $11.1 million, payable in cash or, at the company's election and subject to certain limitations, shares of common stock.
- Standstill and lock-up: Meiji agreed to standstill provisions capping its beneficial ownership at 9.9% for 24 months, and agreed not to transfer the shares through the 365th day following the date of the Purchase Agreement.
- ARCT-154 license: Concurrently, Arcturus Therapeutics, Inc., a wholly owned subsidiary, entered into a license agreement with Meiji relating to the application of ARCT-154 technology for an undisclosed therapeutic area, with Meiji responsible for development and commercialization at its cost.
- Non-binding MOU: The company and Meiji entered into a non-binding memorandum of understanding setting forth principal terms for negotiating an exclusive license to Arcturus's self-amplifying mRNA and lipid nanoparticle technologies for pandemic preparedness and response in Japan.
Arcturus and Meiji Seika Enter $50M Stock Purchase and Collaboration Agreements
According to the Form 8-K filed with the SEC on November 16, 2026 by Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), the company entered into a Securities Purchase Agreement with Meiji Seika Pharma Co., Ltd. on that same date. Under the agreement, the company sold 2,466,395 shares of its common stock to Meiji for a total of $50.0 million. The filing states that the purchase price represents a premium of 80% to the average closing price over the 30 trading days through and including November 11, 2026, and that the closing of the transaction occurred concurrently with the execution of the agreement.
The filing discloses a contingent refund provision: if the company and Meiji do not enter into a definitive license agreement contemplated by the MOU by May 31, 2027, the company is required to refund approximately $11.1 million, representing 50% of the premium, payable in cash or, at the company's election and subject to certain limitations, in shares of common stock. The company also granted Meiji the right to participate in certain future equity issuances for a 24-month period following closing, subject to a 9.9% ownership limitation. The shares were issued in reliance on an exemption from Securities Act registration under Section 4(a)(2). In connection with the sale, the company entered into a Registration Rights Agreement obligating it to file a resale registration statement on Form S-3 no later than the 180th day following closing, or the 30th day following any early termination of the transfer restrictions, whichever is earlier.
Concurrently with the stock purchase, Arcturus Therapeutics, Inc., a wholly owned subsidiary, and Meiji entered into a license agreement for the application of ARCT-154 technology for an undisclosed therapeutic area, with Meiji responsible for development and commercialization at its own cost. The filing also notes a non-binding MOU setting out principal terms for a potential exclusive license to the company's self-amplifying mRNA and lipid nanoparticle technologies for pandemic preparedness and response in Japan, though the filing states that "neither party is obligated to enter into such definitive agreement."
What Was Disclosed
Arcturus Therapeutics Holdings Inc. disclosed a $50.0 million private placement of 2,466,395 common shares to Meiji Seika Pharma Co., Ltd., alongside a concurrent ARCT-154 technology license and a non-binding MOU covering potential pandemic preparedness licensing in Japan, all effective November 16, 2026.



Please wait processing your request...